Liver and Bile
J Hepatol. 2025;83(1):21-30
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition leading to chronic liver disease, which generates substantial healthcare costs. The authors aimed to model the impact of a hypothetical pharmacologic therapy that halts MASLD fibrosis progression on disease and economic burden.
Methods: The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment. Diagnostic costs for all patients and direct costs for patients with MASLD-related liver disease were also incorporated. MASLD disease burden and economic impacts were modeled for five scenarios: a no treatment case and four interventions incorporating the impact of gradually increasing awareness, screening, and diagnosis, and treatment with anti-steatotic therapy and a future, hypothetical therapy that halts fibrosis progression.
Results: Treatment with therapy which only reverses steatosis had minimal (< 1–2%) effect on cumulative chronic liver disease cases and healthcare costs averted. The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11–39%), hepatocellular carcinoma (10–34%), and liver-related deaths (8–31%), a 9–31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.
Conclusions: Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs. Increasing awareness, screening and diagnosis along with introducing pharmacologic therapies that halt fibrosis progression are necessary to realize health and economic benefits for the MASLD population.